NHN Godo gears up to go public on Kosdaq Shopping mall solution developer distributes RFPs to brokerages
Translated by Kim So-in 공개 2021-04-20 07:52:52
이 기사는 2021년 04월 20일 07:46 thebell 에 표출된 기사입니다.
South Korea’s shopping mall solution developer NHN Godo is aiming to go public on the Kosdaq amid booming ecommerce business.NHN Godo sent out a request for proposals (RFP) to domestic major brokerage firms to make its stock market debut, industry sources said on Friday. The company plans to complete the selection process by this month to begin its initial public offering (IPO) preparations in earnest.
The IPO timing has not been decided, but it is likely to speed up the process given that ecommerce companies are starting to get spotlights in the IPO market recently.
NHN Godo is an ecommerce company that was separated from the nation’s tech giant Naver in 2003. Its largest shareholder is NHN, with a 90.33% stake. A fund managed by Keistone Partners is the second largest shareholder.
A shopping mall solution refers to a program necessary to operate an online shopping mall. It is a complex service including product management, ordering, and payment. Main clients include retail companies which intend to expand their business from offline to online.
NHN Godo recorded revenue of 33.2 billion won ($29 million) and operating income of 5.8 billion won in 2020 thanks to the rapid ecommerce growth. If this trend continues into the first half of this year, the company is likely to be valued at its target level.
Market insiders said NHN Godo may be valued at around 1 trillion won given the rapid growth of ecommerce business. If it is valued at the level, Keistone Partners is expected to generate returns of more than six times invested capital.
Keistone Partners acquired 4,945 common shares and 11,927 preferred shares in 2019 through a rights offering. At that time, Keistone Partners valued 100% of NHN Godo at around 150 billion won. (Reporting by Cheol Kang)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [제일약품의 온코닉테라퓨틱 첫 '신약']세번째 P-CAB '자큐보' 2년만에 신약 명맥 잇는다
- 강동그룹, 디아너스CC 품는다
- [제약사 TSR 분석]제일약품, '주가·실적·배당' 3중고 열쇠 '온코닉의 신약'
- (여자)아이들 우기, 'YUQ1' 아이튠즈 앨범차트 10개국 석권
- 박셀바이오, 진행성 간세포암 타깃 'Vax-NK' 특허 출원
- 베니스 비엔날레, 30년만에 두발로 선 '곽훈'의 의미
- [대기업 프로스포츠 전술전략]'모기업발 숙제' 엔씨다이노스, 당분간 긴축 불가피
- 하이브, '민희진 없는' 어도어 경쟁력 입증할까
- SK 오너가 3세 최성환의 '승부수'
- 어느 수집가의 꿈 '이건희 컬렉션'